LATHAM, NY – AngioDynamics Inc. (NASDAQ:ANGO), a medical device manufacturer specializing in surgical and medical instruments, has released its pro forma financial results following a series of divestitures, according to an 8-K filing with the U.S. Securities and Exchange Commission today.
The company reported pro forma financial statements for the fiscal quarters ending August 31, November 30, and February 28 for the years 2022 and 2023, reflecting the impact of selling its dialysis and BioSentry businesses to Merit Medical Systems (NASDAQ:MMSI), Inc. on June 8, 2023.
Additionally, AngioDynamics sold its PICC and Midline product portfolios to Spectrum Vascular on February 24, 2024, and discontinued its RadioFrequency ablation and Syntrax support catheter products as of February 29, 2024.
These strategic moves are part of AngioDynamics' ongoing efforts to optimize its portfolio and focus on core areas of its business. The pro forma results are intended for informational purposes to provide a perspective on the company's financials after the sale of these businesses.
The information provided in this article is based on AngioDynamics' recent SEC filing.
InvestingPro Insights
As AngioDynamics Inc. (NASDAQ:ANGO) navigates through its strategic divestitures to focus on core business areas, investors may find the following metrics and tips from InvestingPro valuable for assessing the company's current financial standing. With a market capitalization of $237.52 million and a negative P/E ratio reflecting recent challenges, AngioDynamics holds a Price to Book ratio of 1.09 as of the last twelve months leading up to Q3 2024. This suggests that the company's stock is trading at a value relatively close to its net asset value. Additionally, the firm's revenue for the same period stands at $324.01 million, though it experienced a revenue decline of 3.19%.
From an operational standpoint, AngioDynamics has demonstrated a strong gross profit margin of 49.27%, indicating a solid capability to control the cost of goods sold and maintain profitability at the gross level. However, it is important to note that analysts have revised their earnings expectations downwards for the upcoming period and do not anticipate the company to be profitable this year. In line with this, InvestingPro Tips highlight that AngioDynamics has not been profitable over the last twelve months and does not pay a dividend to shareholders, which could be a consideration for income-focused investors.
For those looking to delve deeper into the financial health and future prospects of AngioDynamics, there are additional InvestingPro Tips available. These include insights such as the company's cash position relative to its debt and its liquid assets versus short-term obligations. For access to these valuable tips and more, consider visiting https://www.investing.com/pro/ANGO and using the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription. In total, there are 9 additional InvestingPro Tips available for AngioDynamics, which could further inform investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.